Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

Fig. 4

Panobinostat treatment leads to the deposition of activating histone marks which can be enhanced by erlotinib. Non-cytotoxic concentrations of PS induced acetylation of histone H3, which is further increased by combination with erlotinib in both adenocarcinoma cell lines HCC827 and A549. Also, the activating mono-, di- and tri-methylated H3K4 marks were at least additively induced after combination treatment in HCC827 and A549 compared to single agent treatment with PS or erlotinib. In NCI-H460, erlotinib had no additional effect on PS-induced histone acetylation and methylation

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us